Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sandy Geeganage
Institution:
Prelude Therapeutics Incorporated (United States)
Observed institution:
Prelude Therapeutics Incorporated (United States)
ORCID:
0009-0002-4608-8012
Observed ORCID:
0009-0002-4608-8012
OpenAlex ID:
A5004633647
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
2025
·
Michael Hulse
, Min Wang
, et al.
·
Cancer Research
·
31
Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2
2024
·
Artem Shvartsbart
, Koichi Ito
, et al.
·
Cancer Research
·
4
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
2023
·
Koichi Ito
, Michael Hulse
, et al.
·
Molecular Cancer Therapeutics
·
4
Abstract 5793: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile
2026
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789
2025
·
Min Wang
, Miles Cowart
, et al.
·
Cancer Research
·
2
Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
2025
·
Monisha Sivakumar
, Sarah Pawley
, et al.
·
Cancer Research
·
2
Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789
2023
·
Min Wang
, Andrew Moore
, et al.
·
Molecular Cancer Therapeutics
·
1
Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer
2023
·
Yue Zou
, Srijita Dhar
, et al.
·
Cancer Research
·
1
Discovery of Tetrasubstituted Quinazolin-4(3 H )-ones as Wild-type-sparing, Highly Selective PI3KαH1047R Inhibitors
2026
·
Chun Chen
, Ryan Holmes
, et al.
·
Journal of Medicinal Chemistry
Figure S10 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S11 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S5 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S7 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S3 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Figure S8 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Data from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Table S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026
·
Michael Hulse
, Min Wang
, et al.
Show more works
View as search
Works count:
30
Citation count:
47
H-index:
3
I10-index:
1
Year
Topic
Type